http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Rolf Richter (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Hannah Woopen,Klaus Pietzner,Rolf Richter,Christina Fotopoulou,Thomas Joens,Elena Ioana Braicu,Håkan Mellstedt,Sven Mahner,Horst Lindhofer,Silvia Darb-Esfahani,Carsten Denkert,Jalid Sehouli 대한부인종양학회 2014 Journal of Gynecologic Oncology Vol.25 No.3
Objective: Epithelial cell adhesion molecule (EpCAM) has experienced a renaissance lately as a binding site for targeted therapy as well as a prognostic marker in epithelial malignancies. Aim of this study was to study EpCAM as a potential prognostic marker in epithelial ovarian cancer (EOC). Methods: EpCAM expression was assessed by immunohistochemistry on paraffin-embedded primary EOC-tissue samples. EpCAM overexpression was defined as an expression of EpCAM of 76% to 100%. Tissue samples and clinical data were systematically collected within the international and multicenter “Tumorbank Ovarian Cancer” network. Results: Seventy-four patients, diagnosed with EOC between 1994 and 2009, were included in the study (median age, 56 years; range, 31 to 86 years). The majority of the patients (81.1%) presented with an advanced stage International Federation of Gynecology and Obstetrics (FIGO) III/IV disease. Histology was of the serous type in 41 patients (55.4%), endometrioid in 19 (25.6%), and mucinous in 14 (19%). EpCAM was overexpressed in 87.7%. Serous tumors overexpressed EpCAM significantly more often than mucinous tumors (87.8% vs. 78.6%, p=0.045); while no significant difference was noted between the other histological subgroups. EpCAM overexpression was significantly associated with a better progression free survival and higher response rates to platinum based chemotherapy (p=0.040 and p=0.048, respectively). EpCAM was identified as an independent prognostic marker for overall survival (p=0.022). Conclusion: Our data indicate a significant association of EpCAM overexpression with a more favorable survival in EOC-patients. Serous cancers showed a significant EpCAM overexpression compared to mucinous types. Larger multicenter analyses are warranted to confirm these findings.
-
Fabian Trillsch,Sven Mahner,Bastian Czogalla,Miriam Rottmann,Radoslav Chekerov,Elena Ioana Braicu,Gülten Oskay-Öczelik,Pauline Wimberger,Rolf Richter,Jalid Sehouli 대한부인종양학회 2021 Journal of Gynecologic Oncology Vol.32 No.3
Objective: Patients with platinum-resistant ovarian cancer (PROC) have a high need forreliable prognostic markers. Since significance of primary platinum resistance (PPR) versussecondary platinum resistance (SPR) was identified for patients receiving anti-angiogenictherapy, it has not been confirmed for chemotherapy only. Methods: PROC patients from 3 prospective trials of the NOGGO study group (TOWER,NOGGO-Treosulfan, and TRIAS) were included in this meta-analysis. Exploratory Cox andlogistic regression analyses were performed to correlate progression-free survival (PFS) andoverall survival (OS) with the timing when platinum resistance developed. Results: Of 477 patients, 264 (55.3%) were classified as PPR, compared to 213 (44.7%) withSPR. For patients receiving chemotherapy only, SPR was associated with a significantlylonger median PFS of 3.9 compared to 3.1 months for PPR (hazard ratio [HR]=0.78; p=0.015). SPR versus PPR was confirmed to be an independent prognostic factor for better PFS inmultivariate analysis (HR=0.74; p=0.029). Benefit from adding sorafenib to chemotherapywas mainly seen in PPR (HR=0.40; p<0.001) compared to SPR patients (HR=0.83; p=0.465). Conclusions: Prognostic significance of SPR versus PPR could be elucidated for patientsreceiving chemotherapy only. In contrast to bevacizumab, the multi-kinase inhibitorsorafenib exhibits profound therapeutic efficacy in PPR patients indicating potential toovercome this negative prognostic impact.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
